These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 28949904)
1. A lethal model of disseminated dengue virus type 1 infection in AG129 mice. Milligan GN; Sarathy VV; White MM; Greenberg MB; Campbell GA; Pyles RB; Barrett ADT; Bourne N J Gen Virol; 2017 Oct; 98(10):2507-2519. PubMed ID: 28949904 [TBL] [Abstract][Full Text] [Related]
2. A Dengue Virus Type 4 Model of Disseminated Lethal Infection in AG129 Mice. Milligan GN; Sarathy VV; Infante E; Li L; Campbell GA; Beatty PR; Harris E; Barrett AD; Bourne N PLoS One; 2015; 10(5):e0125476. PubMed ID: 25938762 [TBL] [Abstract][Full Text] [Related]
3. A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. Sarathy VV; White M; Li L; Gorder SR; Pyles RB; Campbell GA; Milligan GN; Bourne N; Barrett AD J Virol; 2015 Jan; 89(2):1254-66. PubMed ID: 25392217 [TBL] [Abstract][Full Text] [Related]
4. Characterization of lethal dengue virus type 4 (DENV-4) TVP-376 infection in mice lacking both IFN-α/β and IFN-γ receptors (AG129) and comparison with the DENV-2 AG129 mouse model. Sarathy VV; Infante E; Li L; Campbell GA; Wang T; Paessler S; Robert Beatty P; Harris E; Milligan GN; Bourne N; Barrett ADT J Gen Virol; 2015 Oct; 96(10):3035-3048. PubMed ID: 26296350 [TBL] [Abstract][Full Text] [Related]
5. Mouse models of dengue virus infection for vaccine testing. Sarathy VV; Milligan GN; Bourne N; Barrett AD Vaccine; 2015 Dec; 33(50):7051-60. PubMed ID: 26478201 [TBL] [Abstract][Full Text] [Related]
6. Characterization of a murine model of non-lethal, symptomatic dengue virus infection. Sarathy VV; White M; Li L; Kaiser JA; Campbell GA; Milligan GN; Bourne N; Barrett ADT Sci Rep; 2018 Mar; 8(1):4900. PubMed ID: 29559699 [TBL] [Abstract][Full Text] [Related]
7. Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. Pinto AK; Brien JD; Lam CY; Johnson S; Chiang C; Hiscott J; Sarathy VV; Barrett AD; Shresta S; Diamond MS mBio; 2015 Sep; 6(5):e01316-15. PubMed ID: 26374123 [TBL] [Abstract][Full Text] [Related]
8. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice. Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279 [TBL] [Abstract][Full Text] [Related]
10. Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008. Milligan GN; White M; Zavala D; Pyles RB; Sarathy VV; Barrett ADT; Bourne N Antiviral Res; 2018 Jun; 154():104-109. PubMed ID: 29665374 [TBL] [Abstract][Full Text] [Related]
11. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1). Gelanew T; Hunsperger E Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531 [TBL] [Abstract][Full Text] [Related]
12. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W Front Immunol; 2018; 9():597. PubMed ID: 29740424 [TBL] [Abstract][Full Text] [Related]
13. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice. Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679 [TBL] [Abstract][Full Text] [Related]
14. The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model. de Oliveira LC; Ribeiro AM; Albarnaz JD; Torres AA; Guimarães LFZ; Pinto AK; Parker S; Doronin K; Brien JD; Buller MR; Bonjardim CA Arch Virol; 2020 Mar; 165(3):671-681. PubMed ID: 31942645 [TBL] [Abstract][Full Text] [Related]
15. CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice. Zellweger RM; Tang WW; Eddy WE; King K; Sanchez MC; Shresta S J Virol; 2015 Jun; 89(12):6494-505. PubMed ID: 25855749 [TBL] [Abstract][Full Text] [Related]
16. Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines. Züst R; Toh YX; Valdés I; Cerny D; Heinrich J; Hermida L; Marcos E; Guillén G; Kalinke U; Shi PY; Fink K J Virol; 2014 Jul; 88(13):7276-85. PubMed ID: 24741106 [TBL] [Abstract][Full Text] [Related]
17. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection. Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366 [TBL] [Abstract][Full Text] [Related]
18. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212 [TBL] [Abstract][Full Text] [Related]
19. Maternal Antibody-Mediated Disease Enhancement in Type I Interferon-Deficient Mice Leads to Lethal Disease Associated with Liver Damage. Martínez Gómez JM; Ong LC; Lam JH; Binte Aman SA; Libau EA; Lee PX; St John AL; Alonso S PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004536. PubMed ID: 27007501 [TBL] [Abstract][Full Text] [Related]
20. The Role of Heterotypic DENV-specific CD8 Talarico LB; Batalle JP; Byrne AB; Brahamian JM; Ferretti A; García AG; Mauri A; Simonetto C; Hijano DR; Lawrence A; Acosta PL; Caballero MT; Paredes Rojas Y; Ibañez LI; Melendi GA; Rey FA; Damonte EB; Harris E; Polack FP EBioMedicine; 2017 Jun; 20():202-216. PubMed ID: 28483582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]